Acute Coronary Syndrome (ACS) Clinical Trial
Official title:
The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients Admitted With STEMI Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Pilot Trial
Verified date | October 2018 |
Source | The Royal Wolverhampton Hospitals NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Major heart attacks are caused by a number of factors, the two major of which are furring up
of a coronary artery with atheroma and then sudden clot formation on this area leading to a
blockage and interruption of blood flow. The clots that lead to heart attacks are largely
made of clotting blood cells (platelets) that in health repair blood vessels and inhibit
spontaneous bleeding. One of the main treatment strategies for heart attacks is to make these
cells less "sticky". Aspirin is a main stay of anti-platelet treatment in the United Kingdom
(UK) and in addition one of three other oral antiplatelet agents acting on the same platelet
activation pathway (P2Y12 receptor) is licensed for use. When a patient is admitted with a
major heart attack, they are treated with emergency primary percutaneous coronary
intervention (PPCI) a technique where a wire and balloon are used to reopen the coronary
artery and then usually a stent (a slotted metal tube) is placed to keep the artery open.
Aspirin and one of the P2Y12 inhibitor agents are given to prevent further clots and all have
been shown to reduce negative events following heart attacks and angioplasty with stent
insertion. There are increasing data, including from our own institution, showing that in the
setting of heart attacks, the oral P2Y12 inhibitors are poorly absorbed and have little
effect at the time of most need, i.e. soon after dosing while the primary PCI is being
performed.
All three current P2Y12 inhibitor agents are taken in tablet form immediately before the
emergency PPCI procedure. It appears that in healthy stable patients these agents take at
least 30 min to 2 hours to have an adequate effect. In heart attack patients the angioplasty
procedure is usually performed well within this timescale. Furthermore, patients who are
having a heart attack do not have normal drug absorption with blood being diverted away from
the stomach and gut activity being suppressed by other drugs such as morphine.
In this current study, patients with major heart attacks will be given our standard oral
agent, Ticagrelor, or the newer intravenous agent Cangrelor prior to PPCI.
Status | Completed |
Enrollment | 100 |
Est. completion date | October 1, 2018 |
Est. primary completion date | October 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients presenting with STEMI eligible for PPCI - Able to give verbal assent pre procedure and written consent following the procedure. - Age =18 years - No contraindication to Cangrelor or Ticagrelor - Thienopyridine naïve If a patient gives verbal assent but is unable to provide a written consent at a later stage due to incapacitation, presumed consent will be continued. The reasons why a patient becomes incapacitated and becomes unable to provide a written consent will be recorded during data collection. Exclusion Criteria: - Be unable to provide verbal assent and written consent - Allergic to Aspirin or any of the P2Y12 antagonists in the trial - Have pre-existing cardiogenic shock - Previous myocardial infarction - Have a concurrent septic or inflammatory disease e.g. rheumatoid arthritis, lupus, and pneumonia. - Already taking a P2Y12 inhibitor - Known bleeding diathesis - Significant active bleeding - History of intracranial hemorrhage - Patients who are being treated with formal anticoagulation (Vitamin K antagonist, Factor II or Xa inhibitors) or have an indication for anticoagulation during the first four hours of the study period. Example is patients known to have atrial fibrillation, pulmonary embolism or deep vein thrombosis. - Known severe renal dysfunction requiring renal replacement therapy. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | The Royal Wolverhampton NHS Trust | Wolverhampton |
Lead Sponsor | Collaborator |
---|---|
The Royal Wolverhampton Hospitals NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Degree of platelet inhibition measured with VerifyNow(R) system, rapid platelet function analyser and also VASP flow cytometry at infarct vessel open time (also known as balloon time) | up to 24-36 hours post dosing | ||
Secondary | Index of Microvascular Resistance (IMR) measurement using pressure wire studies immediately following the PPCI procedure. | 1 hour | ||
Secondary | Measurement of thrombolysis in myocardial infarction (TIMI) flow grade using TIMI Frame Count | 3 Months | ||
Secondary | ST Segment Resolution by ECG | 90-120 minutes post PPCI | ||
Secondary | Infarct size by Peak Troponin post PPCI | 24-36 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00385138 -
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
|
Phase 3 | |
Completed |
NCT01944800 -
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
Completed |
NCT02290080 -
Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers
|
Phase 3 | |
Completed |
NCT02286544 -
Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01405287 -
Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT
|
Phase 2 | |
Completed |
NCT00767507 -
Maintenance of Platelet Inhibition With Cangrelor
|
Phase 2 | |
Completed |
NCT03672097 -
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
|
Phase 4 | |
Completed |
NCT00399880 -
Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes
|
N/A | |
Completed |
NCT02430493 -
Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients
|
N/A | |
Completed |
NCT01994577 -
Optimum Troponin Cutoffs for ACS in the ED
|
||
Completed |
NCT00313300 -
Safety Study of Apixaban in Recent Acute Coronary Syndrome
|
Phase 2 | |
Completed |
NCT02244710 -
EndoTic - Endothelium and Ticagrelor
|
N/A | |
Active, not recruiting |
NCT04090281 -
Implementing Precision Medicine Approaches to Guide Anti-platelet Selection
|
Phase 4 | |
Active, not recruiting |
NCT03581578 -
VITROS Immunodiagnostic Products hs Troponin I
|
||
Recruiting |
NCT04116931 -
OPTImal Management of Antithrombotic Agents: OPTIMA-5
|
Phase 4 | |
Not yet recruiting |
NCT06449274 -
RESTORE Imaging: an OCT-IVUS Imaging Substudy of RESTORE Trial
|
N/A | |
Completed |
NCT02171065 -
PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.
|
N/A | |
Completed |
NCT00855257 -
Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome
|
Phase 3 | |
Completed |
NCT02184884 -
Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery
|
||
Completed |
NCT00932100 -
A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome
|
Phase 2 |